drugset / Trial / NCT02012075

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

NCT02012075

Phase 3 Unknown 316 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus Sustained-release Metoprolol Succinate in Patients With Mild or Moderate Chronic Heart Failure.

Timeline

Start
2013-12
Primary completion
2015-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 18 mg Oral
Subject Carvedilol Other / unclassified 72 mg Oral
Comparator Metoprolol Other / unclassified 11.875 mg Oral
Comparator Metoprolol Other / unclassified 190 mg Oral

Indications